Abstract
Median overall survival (OS) after a glioblastoma (GBM) diagnosis remains approximately 15 months for patients receiving aggressive surgical resection, chemotherapy, and irradiation. However, the management of patients presenting with a poor preoperative Karnofsky Performance Status Scale (KPSS) score (≤ 60%) remains a subject of clinical debate. This retrospective study assessed the outcomes of 123 patients with de-novo GBM and a preoperative KPSS ≤ 60% to determine if surgical tumor volume reduction correlates with improved survival in this vulnerable population.
Introduction
The Karnofsky Performance Status Scale (KPSS) is a standard metric used to quantify a patient's functional impairment and ability to perform daily activities. In neuro-oncology, a KPSS of 70% or higher typically warrants aggressive treatment. Patients scoring 60% or lower—meaning they require assistance for most daily needs—often fall into a clinical "gray zone." Surgeons may hesitate to perform extensive resections on these patients, fearing that the physiological stress of surgery might further diminish quality of life without providing a meaningful survival benefit. This study investigates whether aggressive tumor volume reduction actually extends life for these patients.
Methods
Researchers conducted a retrospective, bicentric study of 123 patients (58 females, 65 males; mean age 67.4 ± 13.4 years) diagnosed with de-novo WHO grade IV glioblastoma between September 2006 and March 2016. All included patients had a preoperative KPSS ≤ 60%.
Key methodological components included:
- Volumetric Analysis: Unlike studies relying on simple linear measurements, this research utilized manual segmentation on 3T MRI scans (preoperative and within 72 hours postoperative) to calculate precise tumor volumes.
- Molecular Profiling: The team assessed the methylation status of the MGMT promoter, a critical genetic marker for predicting response to alkylating chemotherapy.
- Statistical Analysis: Survival was analyzed using Kaplan-Meier estimates, while Cox regression models were employed for multivariate analysis to isolate the impact of tumor volume from variables such as age and genetics.
Results
Of the 123 patients, 75 (61%) underwent surgical resection, while 48 (39%) received only a biopsy. The median preoperative tumor volume was 33.0 cm³, which was reduced to a median postoperative volume of 3.1 cm³ across the cohort. Complete resection of the contrast-enhancing tumor was achieved in 32% of the surgical group.
Survival Outcomes
The median overall survival (OS) for the entire cohort was 123 days. However, a significant survival gap was observed based on the type of intervention:
- Surgical Resection: Median OS of 193 days.
- Biopsy Only: Median OS of 90 days.
Prognostic Factors
Multivariate analysis confirmed three statistically significant predictors of survival:
- Age (p < 0.001): Younger patients had a more favorable prognosis.
- Postoperative Tumor Volume (p = 0.02): Lower residual tumor volume was directly correlated with longer survival.
- MGMT Promoter Status (p = 0.016): Patients with methylated MGMT promoters fared significantly better.
Functional Resilience
While the median KPSS dropped from 60% preoperatively to 50% in the immediate postoperative period (assessed at day 5), nearly half of the patients (45.5%) either remained stable or showed improvement. This suggests that the "functional hit" of surgery is often manageable and does not necessarily lead to a permanent decline in status.
Discussion and Conclusion
The findings suggest that patients with a preoperative KPSS ≤ 60% benefit significantly from aggressive surgical resection and low postoperative residual tumor volumes. The data indicates that surgical intervention can more than double the median survival time compared to biopsy alone in this cohort.
While the study is limited by its retrospective design and potential selection bias, it highlights that a low performance score should not be an absolute contraindication for surgery. Instead, treatment decisions should be made on a case-by-case basis by interdisciplinary boards, considering tumor biology (MGMT status) and the potential for significant volume reduction. Future prospective trials are necessary to further refine these surgical indications for frail patients.
Summary updated